Kerry D. Ingalls's most recent trade in Poseida Therapeutics Inc was a trade of 72,568 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | Kerry D. Ingalls | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 72,568 | 72,568 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Kerry D. Ingalls | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 50,000 | 52,000 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Kerry D. Ingalls | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 7.00 per share. | 17 Nov 2021 | 2,000 | 2,000 | - | 7 | 14,000 | Common Stock |
| Poseida Therapeutics Inc | Kerry D. Ingalls | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 137,000 | 137,000 | - | - | Employee Stock Option (Right to Buy) |